Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Oncology

Background:

• Prostate cancer growth is fueled by androgens produced by Cytochrome P450 17A1 (CYP17A1).
• Current CYP17A1 inhibitor abiraterone has a steroidal scaffold, leading to potential off-target effects due to structural similarity with other steroidogenic enzymes.
• Developing non-steroidal scaffolds offers a strategy for enhanced selectivity towards CYP17A1.

Purpose of the Study:

• To identify and design novel, non-steroidal compounds with high selectivity for CYP17A1.
• To evaluate the inhibitory potential of these compounds against CYP17A1's 17α-hydroxylase and 17,20-lyase activities.
• To assess the selectivity of these compounds against other critical cytochrome P450 enzymes, including CYP2D6, CYP3A4, and CYP21A2.

Main Methods:

• Employed a structure-based virtual screening approach to identify potential non-steroidal CYP17A1 inhibitors.
• Utilized density functional theory (DFT) calculations to refine compound design and predict interactions.
• Conducted in vitro assays to determine the inhibitory activity (IC50 values) and selectivity profiles of the designed compounds.

Main Results:

• Two novel non-steroidal compounds demonstrated potent and selective inhibition of CYP17A1 17α-hydroxylase and 17,20-lyase activities.
• These compounds exhibited IC50 values in the nanomolar range.
• Importantly, the compounds showed no significant affinity for drug-metabolizing enzymes CYP2D6 and CYP3A4, nor for CYP21A2, with the latter confirmed in H295R cells.

Conclusions:

• The identified non-steroidal compounds represent promising candidates for selective CYP17A1 inhibition.
• This approach offers a potential strategy to develop more targeted therapies for prostate cancer with reduced side effects.
• Further investigation into these compounds could lead to improved treatment options for androgen-dependent cancers.